Biosketch Theodor W. Guentert
PK-Insights (PKI) was founded in 2011 by Dr. Theodor W. Guentert – who today takes the role as its Chief Executive Officer.
Theodor W. Guentert is a pharmacist by training and a Clinical Pharmacologist certified by the Swiss Society of Clinical Pharmacology. He received his Ph.D. in Pharmaceutical Chemistry from the University in Basel. After a three-year post-doctoral stay at the Medical Center in San Francisco with studies on the pharmacokinetics and -dynamics of antiarrhythmics in animal and man, he returned 1980 to the School of Pharmacy in Basel to head a research team in analytical methodology and drug metabolism. In 1981 he joined F. Hoffmann-La Roche Ltd. and was soon recognized as a Scientific Expert in non-clinical and clinical pharmacokinetics. While holding a venia docendi since 1981, Dr. Guentert was appointed Associate Professor of Pharmacy at the University of Basel in 1992 and, besides his activities in industry, teaches regularly at the Universities of Basel and at international courses [Biopharmaceutics/ Pharmacokinetics, Drug Metabolism, Analytics]. He is author/ co-author of over 100 publications in peer-reviewed journals and is also co-author of the multi-media based teaching software RIDO, Right Dose First Time, developed through sponsorship of the ECPM.
During his career in the Pharmaceutical Industry Theodor W. Guentert took various scientific roles as project leader and held top leadership positions [Associate Clinical Pharmacology Area Head, Head Drug Metabolism and Pharmacokinetics, Head of Non-clinical Drug Safety and Head of Non-clinical Development, all at F. Hoffmann-La Roche Ltd.]. This broad exposure to scientific, strategic and management tasks in the areas of Pharmaceutical R&D enabled him to take an advisory role in project assessment and development. The combination of industry and academic experience with a wide network with peers in pharmaceutical research and teaching made him apt for the role of Head of Academic Alliances organizing collaborations of the Roche Non-clinical Safety Group with academic partners. His knowledge in specific areas of expertise and in the drug discovery and development process was also the basis for educational activities in academia and in continuous education programs. In recent years he represented Roche in the pan-European Innovative Medicines Initiative (IMI) as Coordinator of the SafeSciMET program aiming at setting up, together with 33 academic and industry consortium members, a post-graduate education and training program in Safety Sciences.
